Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quadvpill intensive blood pressure lowering for atrial fibrillation burden
ACTRN12619000188134Phase 3Terminated
- Sponsor
- Western Sydney Local Health District
- Start
- Oct 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of irbesartan, amlodipine, indapamide and bisoprolol in Atrial fibrillation (AFib) and hypertension (HTN) (2 arms), sponsored by Western Sydney Local Health District. Primary endpoint: Atrial fibrillation burden. Started Oct 2020; status: terminated.
02
Drugs
irbesartanamlodipineindapamidebisoprolol
03
Conditions
Atrial fibrillation (AFib)hypertension (HTN)
Beyond the preview
Go deeper on ACTRN12619000188134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000188134.